Johnson & Johnson (NYSE:JNJ) Stock Sold by Rep. Thomas H. Kean, Jr.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on October 30th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on September 30th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 9/23/2026.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 9/17/2026.
• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 9/17/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 8/27/2026.
• Purchased $1,001 – $15,000 in shares of MasTec (NYSE:MTZ) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 8/10/2026.

Johnson & Johnson Stock Down 0.9%

Shares of NYSE JNJ opened at $270.81 on Tuesday. The business’s 50 day moving average is $265.74 and its two-hundred day moving average is $247.22. Johnson & Johnson has a 52-week low of $185.12 and a 52-week high of $282.02. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm has a market cap of $651.93 billion, a price-to-earnings ratio of 41.03, a PEG ratio of 2.68 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same period last year, the business posted $2.80 EPS. Johnson & Johnson’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s payout ratio is presently 81.21%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its stake in Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares during the period. Deutsche Bank AG boosted its stake in shares of Johnson & Johnson by 8.5% during the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after buying an additional 1,225,676 shares during the last quarter. Amundi lifted its position in shares of Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after purchasing an additional 2,001,139 shares during the last quarter. Jupiter Topco LLC acquired a new position in Johnson & Johnson in the second quarter worth $1,967,399,000. Finally, Janus Henderson Group PLC increased its position in Johnson & Johnson by 1.9% in the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock worth $1,924,323,000 after buying an additional 148,497 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 64,515 shares of company stock worth $17,271,766 in the last three months. 0.16% of the stock is owned by company insiders.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New real-world and observational analyses presented at the TCT 2026 symposium found lower in-hospital and short-term mortality among high-risk percutaneous coronary intervention patients supported by Impella pumps. The findings covered 1,379 patients in U.S. and European hospitals and compared favorably with results from the CHIP-BCIS3 study. Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI
• Positive Sentiment: A separate report cited a 94% success rate in a coronary-device trial, adding to evidence that Impella could improve outcomes in complex coronary procedures. Stronger clinical support could help J&J expand adoption of the devices and reinforce its medical-technology growth strategy. Johnson & Johnson reports 94% success rate in trial of coronary artery device
• Positive Sentiment: Clinicians also reviewed progress in the ongoing PROTECT IV trial, which is expected to provide additional evidence for Impella-supported high-risk procedures. Further positive results could improve confidence in the product’s long-term commercial potential. What Is Johnson & Johnson Signaling With Its New Impella Heart Pump Data?
• Neutral Sentiment: Exchange-traded funds purchased approximately $35.1 million of JNJ shares on October 29, suggesting institutional demand, though the transaction alone does not establish a lasting change in investor sentiment. ETFs Are Buying Johnson & Johnson
• Negative Sentiment: Some coverage questioned whether JNJ is fully valued after strong recent performance, including a reported 6.71% 30-day return and 31.76% year-to-date gain. That raises the risk that positive Impella news is already reflected in the stock and could limit near-term upside. Johnson & Johnson As Impella Data Fuels The Story, Is The Stock Fully Valued?

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Bank of America reiterated a “neutral” rating and issued a $278.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a research note on Friday, October 16th. The Goldman Sachs Group restated a “buy” rating and issued a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Leerink Partners reduced their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. Finally, JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $275.92.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.